Alpha-Adrenergic Antagonists

Phenoxybenzamine forms a permanent covalent bond with alpha-adrenergic receptors, producing irreversible, non-competitive blockade. Because no amount of agonist can displace a covalently bound antagonist, the blockade cannot be overcome by catecholamine surges — which is precisely why it is used for pheochromocytoma. The duration of action depends entirely on new receptor synthesis, taking 24 to 48 hours or longer. Given orally, it has a slow onset and prolonged effect, making it suitable for gradual titration over one to two weeks of preoperative preparation.

Because alpha-2 autoreceptors on presynaptic terminals are also blocked, the normal feedback inhibition of norepinephrine release is removed. Norepinephrine is released without restraint, producing pronounced reflex tachycardia — more severe than with selective alpha-1 blockers. This tachycardia is both a side effect and a clinical marker that adequate peripheral blockade has been achieved during preoperative titration. Other adverse effects include orthostatic hypotension, nasal congestion from mucosal vasodilation, and miosis.

Phentolamine competitively blocks alpha-1 and alpha-2 receptors at the same binding site as catecholamines. Because the blockade is competitive, it can be overcome by sufficiently high agonist concentrations, and its effects terminate as the drug is eliminated. After intravenous administration the onset is within one to two minutes and the duration is 15 to 30 minutes per dose, making it highly titratable for acute hemodynamic emergencies. It cannot be given orally due to extensive first-pass hepatic metabolism.

Phentolamine is the drug of choice for hypertensive emergencies caused by catecholamine excess — pheochromocytoma crisis, tyramine-induced hypertension in patients on monoamine oxidase inhibitors, or cocaine-induced severe hypertension. It directly antagonizes the alpha-1 vasopressor effect driving the blood pressure elevation. It is also used to treat norepinephrine extravasation: infiltrated subcutaneously around the affected area, it blocks local alpha-1 receptors and reverses the vasoconstriction causing ischemic necrosis.

Because vascular alpha-1B receptors are relatively preserved, tamsulosin and silodosin produce much less orthostatic hypotension than prazosin, terazosin, or doxazosin. The first-dose phenomenon is substantially attenuated — patients do not need to take the first dose at bedtime. This favorable tolerability profile, combined with their urological efficacy, makes them first-line pharmacotherapy for benign prostatic hyperplasia-related lower urinary tract symptoms.

The most common drug-specific adverse effect is retrograde ejaculation — semen entering the bladder rather than the urethra during ejaculation, because alpha-1A blockade prevents bladder neck closure during seminal emission. Silodosin, with its higher alpha-1A selectivity, produces retrograde ejaculation in approximately 28 percent of patients compared with 4 to 11 percent for tamsulosin. This is not harmful but is important to counsel patients about before prescribing, as it is a common reason for discontinuation.

Yohimbine blocks alpha-2 autoreceptors on presynaptic adrenergic terminals, removing the feedback inhibition of norepinephrine release. The result is uninhibited norepinephrine exocytosis, raising heart rate, blood pressure, and sympathetic tone. Central alpha-2 blockade in the brainstem increases noradrenergic transmission, producing anxiety, restlessness, and sympathomimetic arousal. These effects are dose-dependent and more pronounced in patients with underlying autonomic dysfunction, hypertension, or anxiety disorders.

Yohimbine has no accepted first-line clinical indication in current practice. It is not recommended for erectile dysfunction (phosphodiesterase type 5 inhibitors are far superior) or for weight loss (evidence is insufficient). Its contraindications are extensive: hypertension, cardiac disease, anxiety disorders, and any condition requiring monoamine-based treatment, where it can precipitate hypertensive crisis. It is used as a pharmacological research probe for studying central noradrenergic systems but this is a specialist application.

Phosphodiesterase type 5 inhibitors (sildenafil, tadalafil, vardenafil) lower blood pressure by increasing cyclic guanosine monophosphate in vascular smooth muscle, causing vasodilation through a mechanism entirely independent of adrenergic receptors. Combined with alpha-1 blockers, which lower blood pressure by blocking alpha-1-mediated vasoconstriction, the result is additive vasodilation that can cause symptomatic, severe hypotension — particularly around the first dose of the alpha-1 blocker or after dose escalation. A minimum separation of four to six hours between these drug classes is required. Tamsulosin has the most favorable interaction profile among the alpha-1 blockers in this combination, though caution remains warranted.

In a patient with complete alpha blockade (as from phenoxybenzamine), the vasopressor response to alpha-1 agonists is eliminated. When epinephrine is given to such a patient, the alpha-1-mediated vasopressor component is blocked while the beta-2-mediated vasodilatory component in skeletal muscle vasculature remains intact. The net result is a paradoxical fall in blood pressure — called epinephrine reversal. This is a classic pharmacological demonstration of the consequence of complete alpha blockade, and has direct clinical implications in the operating room: patients prepared with phenoxybenzamine for pheochromocytoma surgery may require vasopressin or very large doses of norepinephrine to maintain blood pressure after tumor removal, as standard doses of vasopressors may be partially ineffective against the established blockade.